1.000USD0.00%Mkt Cap: 2.68M USDP/E: —Last update: 2026-05-26
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap2.68M USD
Enterprise Value3.26M USD
Revenue (TTM)601.00K USD
Gross Profit-11.94M USD
Net Income (TTM)-18.63M USD
Revenue/Share0.2860 USD
Last Price1.000 USD
Fiscal Year EndDec 2024
MR QuarterDec 2024
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.14
PEG—
EV/EBITDA-0.17
EV/Revenue5.42
P/S4.45
P/B-0.64
EPS (TTM)-8.88
EPS (Forward)-0.14
52W Range
0.310058% of range1.500
52W High1.500 USD
52W Low0.3100 USD
Profitability
Gross Margin0.00%
Oper. Margin-1590.14%
EBITDA Margin0.00%
Profit Margin-3100.50%
ROE748.95%
ROA-717.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.19M USD
CapEx (TTM)22.00K USD
FCF Margin-1920.74%
FCF Yield-431.27%
Net Debt-1.08M USD
Net Debt/EBITDA0.06
Balance Sheet
Debt/Equity-0.01
Current Ratio0.50
Quick Ratio0.38
Book Value/Sh-1.5520 USD
Cash/Share0.4140 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateFeb 20, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.68M
Float1.18M
Insiders11.48%
Institutions45.01%
Short Interest
Short Ratio0.6d
Short % Float3.23%
Short % Out.2.32%
Shares Short62.11K
Short (prev mo.)127.50K
Technical
SMA 501.015 (-1.5%)
SMA 2000.8505 (+17.6%)
Beta0.56
S&P 52W Chg28.31%
Avg Vol (30d)2.04K
Avg Vol (10d)1.60K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—